Cognitive Impairment in Diabetes

Cognitive Impairment in Diabetes - COG-ID

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39732

Enrollment

228

Registered

2012-05-30

Start date

2012-08-16

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adult onset diabetes mellitus type 2 diabetes

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Diagnosis of type 2 diabetes and aged 70 years or older

Exclusion criteria

Exclusion criteria: - Patients with a previous diagnosis of cognitive problems or dementia - Patients unable or unwilling to give written informed consent - Not capable of writing and reading in Dutch

Design outcomes

Secondary

Measure	Time frame
Secundary outcome of the study will be a a detailed characterisation (cognitive profile, brain MRI, diagnosis) of a population based sample of patients with T2DM and cognitive impairment. Furthermore, we will examine the effect of the diagnostic procedure on diabetes care and patients* quality of life six and twenty-four months after a diagnosis of cognitive dysfunction.	—

Primary

Measure	Time frame
The main study outcome is a diagnosis of cognitive impairment, defined as either MCI or dementia, regardless of the underlying etiology. The diagnosis will be established at the memory clinic at a multidisciplinary team meeting with a rigorous standardized work-up and according to internationally accepted diagnostic criteria. With this outcome we can calculate the accuracy of the screening instruments and the GP evaluation.	—

Measure

Time frame

The main study outcome is a diagnosis of cognitive impairment, defined as either MCI or dementia, regardless of the underlying etiology. The diagnosis will be established at the memory clinic at a multidisciplinary team meeting with a rigorous standardized work-up and according to internationally accepted diagnostic criteria. With this outcome we can calculate the accuracy of the screening instruments and the GP evaluation.

—

Countries

Netherlands

Outcome results